Dravet Syndrome & SCN1A Spectrum
Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy with onset in the first year of life, historically known as severe myoclonic epilepsy of infancy (SMEI). It is caused in more than 80% of cases by loss-of-function pathogenic variants in the SCN1A gene, which encodes the voltage-gated sodium channel α-subunit NaV1.1—a channel predominantly expressed in GABAergic inhibitory interneurons. The resulting haploinsufficiency of NaV1.1 leads to reduced inhibitory interneuron excitability, disrupting the excitation-inhibition balance in cortical and hippocampal networks. Clinically, Dravet syndrome presents with prolonged, fever-sensitive seizures in the first year of life in a previously healthy infant, followed by the emergence of multiple seizure types, developmental plateau or regression, and lifelong drug-resistant epilepsy. The therapeutic landscape has evolved substantially over the past decade with the approval of stiripentol, cannabidiol, and fenfluramine, though seizure freedom remains rare and avoidance of sodium channel-blocking antiseizure medications is a critical management principle.
Bottom Line
- Genetics: >80% of patients have SCN1A pathogenic variants (de novo in ~95%); loss-of-function mechanism causing NaV1.1 haploinsufficiency; rare cases linked to GABRG2, GABRA1, STXBP1, PCDH19, or SCN1B
- Pathophysiology: NaV1.1 is predominantly expressed in GABAergic inhibitory interneurons; haploinsufficiency reduces inhibitory neuron firing → excitation-inhibition imbalance → seizure susceptibility, particularly with thermal triggers
- Clinical hallmark: Prolonged, hemiclonic or generalized clonic seizures triggered by fever in the first year of life; evolution to multiple seizure types (myoclonic, atypical absence, focal); developmental plateau/regression after the first year; gait abnormalities (crouch gait)
- Treatment: Valproate + clobazam as backbone therapy; stiripentol, cannabidiol, and fenfluramine as evidence-based add-on therapies; ketogenic diet as adjunctive treatment
- CRITICAL: Sodium channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) are CONTRAINDICATED—they worsen seizures and can provoke status epilepticus
- Prognosis: Drug-resistant epilepsy in >90%; intellectual disability (moderate to severe) in the majority; SUDEP risk is elevated (~15% lifetime risk); life expectancy is reduced
Genetics and Pathophysiology
SCN1A Gene and NaV1.1 Channel
The SCN1A gene (chromosome 2q24.3) encodes the α-subunit of the voltage-gated sodium channel NaV1.1. This channel is a critical component of action potential generation and propagation in neurons. The key to understanding Dravet syndrome lies in the cell-type-specific expression pattern of NaV1.1:
- GABAergic interneurons: NaV1.1 is the predominant sodium channel α-subunit in parvalbumin-positive and somatostatin-positive inhibitory interneurons in the cortex and hippocampus
- Haploinsufficiency: Loss-of-function variants in SCN1A reduce the number of functional NaV1.1 channels, selectively impairing the firing capacity of inhibitory interneurons
- Excitation-inhibition imbalance: Reduced interneuron excitability leads to decreased GABAergic inhibition of excitatory principal neurons → hyperexcitable cortical networks → seizure generation
- Temperature sensitivity: NaV1.1-dependent interneuron function is particularly impaired at elevated temperatures, explaining the characteristic fever-triggered seizures
Genotype-Phenotype Correlations
| Genetic Finding | Frequency in DS | Variant Type | Clinical Correlation |
|---|---|---|---|
| SCN1A truncating variants | ~40–50% of all DS | Nonsense, frameshift, splice site → premature stop codon → haploinsufficiency | Typically associated with more severe phenotype; earlier onset; higher seizure burden |
| SCN1A missense variants | ~35–40% of all DS | Single amino acid substitution in critical channel domains (pore, voltage sensor) | Variable severity; some missense variants may produce milder phenotypes (GEFS+ spectrum) |
| SCN1A deletions | ~5–10% | Whole-gene or partial-gene deletions (detected by MLPA or array CGH) | Complete loss of one allele; severe phenotype |
| SCN1A-negative DS | ~15–20% | Phenotypic Dravet without SCN1A variant; alternative genes: GABRG2, GABRA1, STXBP1, PCDH19, SCN1B, SCN2A, HCN1 | Clinical overlap with DS but may differ in treatment response; PCDH19 causes a Dravet-like phenotype in females |
The SCN1A Spectrum
- SCN1A pathogenic variants cause a spectrum of epilepsy phenotypes ranging from mild to severe:
- Mildest: Genetic epilepsy with febrile seizures plus (GEFS+)—febrile seizures persisting beyond age 6, often with afebrile seizures; usually well-controlled; often inherited (autosomal dominant)
- Intermediate: Borderline or "atypical" Dravet syndrome—some features of DS but less severe developmental impairment or fewer seizure types
- Severest: Classic Dravet syndrome—drug-resistant, progressive encephalopathy
- The same SCN1A variant can produce different phenotypes in different family members (variable expressivity), underscoring the role of genetic modifiers and environmental factors
- Dravet syndrome remains a clinical diagnosis; the presence of an SCN1A variant alone is insufficient without the characteristic clinical phenotype
Clinical Features
Natural History by Age
| Age Period | Clinical Features | EEG Findings |
|---|---|---|
| 0–6 months | Normal development; no seizures | Normal |
| 6–12 months (onset) | Prolonged (>15 min), hemiclonic or generalized clonic seizures triggered by fever or vaccination; seizures may alternate sides; often presents to the ED as febrile status epilepticus | Often normal or nonspecific; may show mild slowing |
| 1–4 years | Seizures become afebrile and more frequent; new seizure types emerge: myoclonic jerks, atypical absences, focal seizures with impaired awareness; prolonged seizures and status epilepticus are common; developmental plateau or regression becomes apparent; language delay is often the earliest cognitive concern | Generalized and focal/multifocal epileptiform discharges; background slowing becomes apparent; photosensitivity may emerge |
| 4–10 years | Drug-resistant epilepsy with multiple seizure types; myoclonic seizures may be prominent; intellectual disability becomes more evident; gait abnormalities develop (wide-based, crouched gait); behavioral challenges (hyperactivity, autistic features) | Diffuse slowing; multifocal and generalized discharges; photosensitivity in ~30% |
| Adolescence/adulthood | Seizure frequency may decrease somewhat but rarely ceases; convulsive seizures often become nocturnal; myoclonic seizures may diminish; intellectual disability is stable (moderate to severe); crouch gait progresses; SUDEP risk is highest | Generalized slowing; epileptiform discharges may become less prominent; background remains abnormal |
Associated Features
- Gait abnormalities: Progressive crouch gait with hip and knee flexion, often requiring orthotics or assistive devices; attributed to combined cerebellar, pyramidal, and extrapyramidal dysfunction
- Autonomic dysfunction: Temperature dysregulation, excessive sweating
- Nutritional concerns: Feeding difficulties, weight gain (valproate, stiripentol), or weight loss (topiramate, cannabidiol)
- Sleep disturbances: Fragmented sleep; nocturnal seizures
Diagnosis
Dravet syndrome is a clinical diagnosis supported by genetic testing:
- Clinical criteria (ILAE 2022): Onset in the first year of life in a normally developing infant; prolonged, hemiclonic or generalized clonic seizures, often triggered by fever or heat; evolution to multiple seizure types; developmental plateau or regression; drug-resistant epilepsy
- Genetic confirmation: SCN1A pathogenic variant identified in >80%; negative SCN1A testing does not exclude the diagnosis; consider expanded panel or exome sequencing
- Exclusion of structural causes: Brain MRI is typically normal in early stages; progressive hippocampal sclerosis may develop in later stages
Diagnostic Pitfalls
- The first seizure in Dravet syndrome is often a prolonged febrile seizure, leading to an initial diagnosis of "complex febrile seizure"—the diagnosis of DS is often not made until the second year of life when additional seizure types and developmental concerns emerge
- An SCN1A variant of unknown significance (VUS) does NOT confirm the diagnosis—the phenotype must be consistent; some VUS are later reclassified as benign
- Not all patients with SCN1A pathogenic variants have Dravet syndrome—milder phenotypes (GEFS+) exist on the same spectrum
- Patients may initially respond to sodium channel blockers, only to have dramatic worsening weeks later; any infant with febrile seizures in the first year who worsens on carbamazepine, oxcarbazepine, or phenytoin should be evaluated for Dravet syndrome
Treatment
Pharmacotherapy
| Medication | Role | Evidence | Key Notes |
|---|---|---|---|
| Valproate | First-line; broad-spectrum backbone therapy | Long-standing clinical experience; reduces seizure frequency in most patients | Weight gain, tremor, hepatotoxicity; teratogenic; check POLG before use in children <2 years (risk of fatal hepatotoxicity in POLG-related disease) |
| Clobazam | First-line add-on; effective against multiple seizure types | Clinical experience; foundation of most DS treatment regimens; synergistic with stiripentol | Sedation, drooling; tolerance may develop; CYP2C19 genotype affects metabolism; commonly combined with valproate |
| Stiripentol | FDA-approved add-on for DS (age ≥2); used with valproate + clobazam | STICLO France trial: 71% responder rate (≥50% seizure reduction) vs. 5% placebo; always used in combination with valproate and clobazam | Inhibits CYP2C19 and CYP3A4 (increases clobazam and N-desmethylclobazam levels); dose reduction of clobazam often needed; appetite loss, weight loss, drowsiness |
| Cannabidiol (Epidiolex) | FDA-approved add-on for DS (age ≥1) | Phase 3 trials: 43% responder rate vs. 27% placebo; significant reduction in convulsive seizure frequency | Hepatotoxicity (especially with concomitant valproate; monitor LFTs); increases N-desmethylclobazam; somnolence, diarrhea, decreased appetite |
| Fenfluramine (Fintepla) | FDA-approved add-on for DS (age ≥2) | Phase 3 trials: 62–68% responder rate vs. 1–10% placebo; some patients achieved near seizure freedom; long-term data show sustained efficacy | Requires cardiac monitoring (echocardiogram before, during, and after treatment; risk of valvular heart disease and pulmonary arterial hypertension); REMS program; decreased appetite |
| Topiramate | Adjunctive therapy | Clinical experience; reduces seizure frequency in some patients | Cognitive side effects; metabolic acidosis; weight loss; nephrolithiasis |
| Levetiracetam | Adjunctive therapy | Modest efficacy; sometimes used early before diagnosis is confirmed | Behavioral side effects (irritability, aggression); generally safe but limited efficacy in DS |
Medications CONTRAINDICATED in Dravet Syndrome
- Carbamazepine (Tegretol): Sodium channel blocker → further impairs NaV1.1-dependent inhibitory interneuron function → worsens seizures; may trigger status epilepticus
- Oxcarbazepine (Trileptal): Same mechanism as carbamazepine; equally harmful in DS
- Phenytoin (Dilantin): Sodium channel blocker; worsens seizures in DS
- Lamotrigine (Lamictal): Sodium channel blocker; can worsen seizures, particularly myoclonic seizures, in DS
- Lacosamide (Vimpat): Enhances slow inactivation of sodium channels; may worsen seizures in DS (limited data, but generally avoided)
- Vigabatrin: May worsen seizures in DS
- Rationale: All sodium channel blockers reduce the activity of the already compromised NaV1.1 channel in inhibitory interneurons, further tilting the excitation-inhibition balance toward hyperexcitability
Nonpharmacologic Therapies
- Ketogenic diet: Effective adjunctive therapy in DS; approximately 50–70% of patients achieve ≥50% seizure reduction; particularly useful when multiple medications are poorly tolerated
- Vagus nerve stimulation (VNS): Adjunctive option for drug-resistant DS; modest efficacy (~40–50% responder rate)
- Seizure triggers avoidance: Hyperthermia (hot baths, prolonged sun exposure, excessive physical activity in heat), fever (aggressive antipyretic management), photic stimulation (in photosensitive patients), and sleep deprivation should be minimized
Emerging and Investigational Therapies
- Antisense oligonucleotides (ASOs): STK-001 (now in phase 3) targets the nonproductive SCN1A mRNA splice variant to increase functional NaV1.1 protein expression; intrathecally administered; the first precision therapy directly addressing the genetic mechanism of Dravet syndrome
- SCN1A gene therapy: Multiple approaches in preclinical development, including gene replacement (AAV vectors) and transcriptional activation (CRISPRa)
- Soticlestat (TAK-935/OV935): Cholesterol 24-hydroxylase inhibitor; modulates brain cholesterol metabolism and neuronal excitability; phase 2 data showed mixed results
Differential Diagnosis of Dravet Syndrome
Several conditions may initially mimic Dravet syndrome, particularly in the early stages when the only manifestation is prolonged febrile seizures:
| Condition | Distinguishing Features | Key Differences From Dravet |
|---|---|---|
| Complex febrile seizures | Prolonged or focal febrile seizures in a normally developing child; benign course in most | No afebrile seizures; normal development; seizures do not recur frequently; no SCN1A variant |
| GEFS+ (genetic epilepsy with febrile seizures plus) | Febrile seizures beyond age 6, ± afebrile seizures; often familial; well-controlled | Less severe than DS; normal cognition; seizures usually respond to standard ASMs; may have inherited SCN1A variant |
| PCDH19-related epilepsy | Dravet-like phenotype in females; seizure clusters triggered by fever; onset 6–36 months | Cluster pattern with seizure-free intervals; males are typically unaffected carriers; intellectual disability variable; X-linked with male sparing |
| SCN2A-related epilepsy | Neonatal or infantile-onset seizures; variable phenotype from self-limited to severe DEE | Earlier onset (often neonatal); sodium channel blockers may be effective (unlike Dravet); gain-of-function variants in early-onset, loss-of-function in later-onset |
| SCN8A-related epilepsy | Infantile-onset epileptic encephalopathy; gain-of-function variants | Sodium channel blockers may be effective for SCN8A gain-of-function (opposite of Dravet); earlier onset; more prominent tonic seizures |
| Infantile epileptic spasms syndrome | Epileptic spasms in clusters; hypsarrhythmia | Spasms (not hemiclonic seizures) are the hallmark; hypsarrhythmia on EEG; different treatment (ACTH/vigabatrin); spasms are uncommon in Dravet |
Seizure Emergency Management in Dravet Syndrome
Prolonged seizures and status epilepticus are common in Dravet syndrome and represent the most immediate life-threatening complications. All caregivers should have a comprehensive seizure action plan:
- Rescue benzodiazepines: Intranasal midazolam (0.2 mg/kg, max 10 mg) or rectal diazepam (0.3–0.5 mg/kg, max 20 mg) should be administered for any seizure lasting >5 minutes; many DS families are trained to administer these at home
- Emergency department management: IV benzodiazepines (lorazepam, midazolam) for ongoing seizures; avoid IV phenytoin and fosphenytoin (sodium channel blockers); levetiracetam IV is a safer second-line option in the ED
- Active cooling: Aggressive temperature management for fever-associated seizures; antipyretics should be administered early and proactively during febrile illnesses
- Medical alert identification: Patients with DS should wear medical alert identification listing the contraindication of sodium channel blockers to prevent inadvertent administration in emergency settings
- Vaccination considerations: Vaccination may trigger prolonged febrile seizures in DS; this does NOT constitute a contraindication to vaccination; premedication with antipyretics and close monitoring after vaccination are recommended; the benefits of vaccination outweigh the risks
SUDEP Risk and Long-Term Prognosis
Dravet syndrome carries one of the highest SUDEP risks among all epilepsy syndromes:
- Estimated lifetime SUDEP risk of approximately 15–20%
- SUDEP risk is highest in adolescence and young adulthood, when generalized tonic-clonic seizures are most frequent
- Nocturnal seizure monitoring (seizure detection devices, video monitors) is recommended
- Aggressive seizure management—particularly reduction of GTC frequency—is the most important strategy for reducing SUDEP risk
- Overall mortality in DS is approximately 15–20% by adulthood, with SUDEP, status epilepticus, and accidental death as leading causes
Key Management Principles
- Confirm the diagnosis early with SCN1A genetic testing in any infant with prolonged febrile seizures in the first year of life, particularly if seizures are hemiclonic or triggered by low-grade fever/vaccination
- Avoid sodium channel blockers at all stages of the disease; educate all caregivers and providers (ED, anesthesia, primary care) about this contraindication
- Use a combination of valproate + clobazam as the backbone, adding stiripentol, cannabidiol, or fenfluramine based on seizure control, tolerability, and drug interactions
- Institute a comprehensive care plan: seizure action plan with rescue medication (intranasal midazolam, rectal diazepam); developmental and behavioral support; physical therapy for gait abnormalities; nutritional support
- Screen for SUDEP risk; recommend nocturnal monitoring and optimize GTC seizure control
- Prepare for transition to adult epilepsy care, including guardianship planning, vocational support, and residential services
References
- Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia 2022;63(6):1349–1397.
- Claes L, Del-Favero J, Ceulemans B, et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68(6):1327–1332.
- Wirrell EC, Laux L, Donner E, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. Pediatr Neurol 2017;68:18–34.e3.
- Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet 2000;356(9242):1638–1642.
- Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017;376(21):2011–2020.
- Lagae L, Sullivan J, Knupp K, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2019;394(10216):2243–2254.
- Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol 2020;77(3):300–308.
- Han Z, Chen C, Christiansen A, et al. Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome. Sci Transl Med 2020;12(558):eaaz6100.
- Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. Epilepsy Res 2016;128:43–47.
- Scheffer IE, Nabbout R. SCN1A-related phenotypes: epilepsy and beyond. Epilepsia 2019;60(Suppl 3):S17–S24.
- Guerrini R, Dravet C. Severe epileptic encephalopathies of infancy, other than West syndrome. In: Epileptic Syndromes in Infancy, Childhood and Adolescence. 6th ed. John Libbey Eurotext; 2019:89–133.